9999999997-13-000203.txt : 20130111
9999999997-13-000203.hdr.sgml : 20130111
20130111151007
ACCESSION NUMBER: 9999999997-13-000203
CONFORMED SUBMISSION TYPE: CT ORDER
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20130111
DATE AS OF CHANGE: 20130111
20130111
20130111
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cyclacel Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001130166
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 911766850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: CT ORDER
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50626
FILM NUMBER: 13525316
BUSINESS ADDRESS:
STREET 1: 200 CONNELL DRIVE
STREET 2: SUITE 1500
CITY: BERKELEY HEIGHTS
STATE: NJ
ZIP: 07922
BUSINESS PHONE: 908-517-7330
MAIL ADDRESS:
STREET 1: 200 CONNELL DRIVE
STREET 2: SUITE 1500
CITY: BERKELEY HEIGHTS
STATE: NJ
ZIP: 07922
FORMER COMPANY:
FORMER CONFORMED NAME: XCYTE THERAPIES INC
DATE OF NAME CHANGE: 20001218
CT ORDER
1
filename1.pdf
begin 644 filename1.pdf
M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S
M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR
M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T
M:"`V,B]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``+V7PRH@!&(61@X&I#%
MF*&8@:&1@9N!_95=`U2E2#U41QM8%X/R-PB?D1\@P`#W)08M#0IE;F1S=')E
M86T-96YD;V)J#3$Q(#`@;V)J#3P\+TUE=&%D871A(#(@,"!2+U!A9V5,86)E
M;',@-B`P(%(O4&%G97,@."`P(%(O5'EP92]#871A;&]G/CX-96YD;V)J#3$R
M(#`@;V)J#3P\+T-O;G1E;G1S(#$T(#`@4B]#%LP(#`@-C$R(#7!E+T]B:E-T;3X^\AT\44VE$#2
M-MU@R4)MVD'(@^9HB<&78*LL_??3D>S8+82-!B'I^'SG\AWK8R%08`)$#"P"
MYIDK!D]PX-3X?.`,'S0VY/^F'1$NMC/V0,,RB\#B=DD5=:>-+4X[)QF=,
MF^G@=5-GB=(;LKY;D%2=]'8Z->$_UO!;%JTRQA(826;=9[($^H5RDKX>U="3
MU$>'V]Q9FZE*0Q0S*Q+67VVV$J6BEC$`-:_3B;SNM@M
M4XLGNE$Z.Y!5W92RL*YG1TD81M^T+/)L5NT+!90D6I5/YC^';CZ,136KVOS\O9`,>?]<%'QH?Z;OL
M(A@WO__EET9":?.B++,S/5-ZIP_MA@<4<`74W>.%F.=YX&(PXM(>6^,E..].
MW&$H(&0,A(CL]J*XRT$D]GT7:1",A?4&+$KQ/B1S7(Z34:'!:^
M".[_5^%9L]U[CQ5H===I")75O[7M$L76CKH;L3['Q;U5VWBA?K#W^+9:ZCB-
MM8>J?L^Y[\]'F-4\[57X5X`!`*'GB5L-"F5N9'-T?%9;;^)&%'[G5QRI+^,*SWJ,;#A+_X;>3#T
M8AH'D+SV/'C!OR23'V\]`D[R3X_%X#+*0DBFYD[RJSFX`SH:G9ZZU//82+J;
MPUOO.WE:+I*9XP9T1*:P=MR0#DGB4$;&B;X[,S?!^2NY[[D1'0[#RYA>9&+*
M@XRYGDV>5HMDX:!U@`%@O)P")AG0B/PQ^3I>WID+F#P^/"S6Z\7C4H='^^%5
M\($)[L>JY_OQ\FF\^A,8ZX/OL8%NE`WHT#LKZQJDD(ZBJ[@6",\`\;B:SE9P
MY[@Q-K\:+Y/%\@[K6\Y58(>^]EY,9^@Q_@;):C9.'O#"X(6.
M47A6F7'6T,N,R=<96,`0JID!",:3!![GP$8#B;]/`A,0N0@^Z)0Q+/0JGX+0
M@BDS3PY9D6:\@-]V3D1#DM:O>-FU(DN+I@^+,J-.2`?$DA*&'V1$DL/@3(-S
M47!85A0PGQMZD8_(PV3^BQ\'4:QKI/Z9+,G?MWZ4(0Y$H`="XFAT%YR4[EWV
M&=H^&=-]@N/ZP]!#I9UW'.J.G1@[O&X;FFZCGXBVY3FD):3[?8$6K:A*Z,I<
MN?,:5AVVZ0<;U]X33>XYC8&J@OSH
MTD)L!6]DIQ<\9M7K*Z\S>43VMD+I&M=7%)YM"=-*F9;*4&64.$7D/"^*"O4D
M29O7G.>5?@;5UK*DPQY9PFUC2V1
MI^+?HZA\4^*)B>^DD5$PXZ2J]U6M@\Z%+)S##GO/>576.4U(H`''I1"?!'^?9#M6A
M?Y+[YBRAMH]CR3FLH_V])4W/_=KV9`5#I<
M@L'(O+``[)"#HR:%>92!PT9!*"&HJ^YE9Y[(H34V0=^,_'S>4K:]"5Z'4:
MJ"K4NCT5`K?V[3L$[,S.#003'!*%@6BDP/IR7*T:C>*L*$?L!N],2^B6*ONH
MJ+KITE*I2W\)4%$^JI#D2.M+JA9[U^ZJ6K2'SQ;D&[B_/QS?_8J)^,@$_MQ7
MN])@N^*'LBJ0:[M2+M"T#F-I[..H-W@(1N<'(0]RV(YW6GLGE0?\0DA*Z1Z>
M'IC<4QM5Z`/N?.6!.C2.F3T<72L=2AJ&]JUO$;G"8);T_A-@`-$)L!<-"F5N
M9'-T
M,E,P4#!7,+10L+'1]RO-+8X&<0T4@F+M[(`BP?HN=G8``08`C84(-PT*96YD
MFMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN#IX;7!T:STB061O8F4@6$U0
M($-O"UN&%P+S$N,"\B/@H@("`@("`@("`\>&UP.D-R96%T941A=&4^,C`Q,RTP
M,2TQ,50Q-3HP-SHQ-RTP-3HP,#PO>&UP.D-R96%T941A=&4^"B`@("`@("`@
M(#QX;7`Z0W)E871O&UL;G,Z<&1F/2)H='1P.B\O;G,N
M861O8F4N8V]M+W!D9B\Q+C,O(CX*("`@("`@("`@/'!D9CI0&UP
M34TZ26YS=&%N8V5)1#YU=6ED.F8R,#(Q.3EF+6$U-#@M-#)C.2UB.3!A+3EF
M865E-#)F-64Y-CPO>&UP34TZ26YS=&%N8V5)1#X*("`@("`@/"]R9&8Z1&5S
M8W)I<'1I;VX^"B`@(#POJ'5!:DZ@
M?(RQ"L(P%$5_Y6U-!M.D6D0102PX50L575QB$O%!:.3UB>C7F\'9.YWAG+L`
M#:M5N7GR/9'8H_U@+\LM!M"S'CCNS`<"`?2*[77P$&`-Z<0Y\-"F5N
M9'-TF4@,3`O5'EP92]84F5F+U=;,2`R(#%=/CYS=')E86T-
M"FC>8F(``B9&KMD,3`R,;4""+P7$Z@41_$")IP^`+`8&1B#!]!](,#(`!!@`
M=/`%&PT*96YD